Clinical and demographic factors associated with early relapse in patients with schizophrenia: a naturalistic observation study

Gündoğmuş, İbrahi̇m; Aydin, Mikail Burak; Öz, Sefa; Taşçi, Azize Beril; Uzun, Özcan

doi:10.1097/yic.0000000000000377

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the higher the number of previous hospitalizations, the higher the likelihood of rehospitalization. This is an interesting finding consistent with the literature on people with schizophrenia, where the number of previous hospitalizations was a predictor of early relapse (Gündoğmuş et al, 2021).…”

Section: Discussionsupporting

confidence: 91%

A Brief Psychoeducation Intervention to Prevent Rehospitalization in Severe Mental Disorder Inpatients

Riera-Molist

Riera-Morera²,

Roura-Poch

et al. 2022

J Nerv Ment Dis

View full text Add to dashboard Cite

The efficacy of medium- to long-term psychoeducation in preventing relapse and hospitalization in people with severe mental disorders (SMDs) is robust. However, the evidence is inconclusive in brief interventions and individual modalities. The aim of this randomized clinical trial in SMD inpatients is to analyze the efficacy of a brief psychoeducation intervention added to treatment-as-usual, in improving the rehospitalization rate at 3 and 6 months after discharge. Fifty-one SMD inpatients were randomized to the intervention (n = 24) or control group (n = 27). Low insight and poor medication adherence were the most prevalent risk factors at admission. No significant differences were observed in the rehospitalization rate at 3 and 6 months after discharge. On the overall sample, the number of previous hospitalizations was a rehospitalization predictor at 3 (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.01–1.56; p = 0.04) and 6 months (OR, 1.85; 95% CI, 1.17–2.91; p = 0.009). SMD people require multimodal and persistent approaches focused on insight and medication adherence to prevent rehospitalizations.

show abstract

Section: Discussionsupporting

confidence: 91%

A Brief Psychoeducation Intervention to Prevent Rehospitalization in Severe Mental Disorder Inpatients

Riera-Molist

Riera-Morera²,

Roura-Poch

et al. 2022

J Nerv Ment Dis

View full text Add to dashboard Cite

show abstract

“…In addition, any episode of relapse constitutes a neurotoxic insult [73]. Over the years, a growing number of studies, in which participants were treated with newer drugs, confirmed relapse rates of between 20 and 38%, with peaks of up to 45% when maintenance treatment was discontinued [34,74,75]. In this perspective, Clozapine, considered the most potent drug in many randomised, prospective head-to-head trials, could also be used as a first-line treatment, in order to prevent early relapses and initial therapeutic failures [18,76].…”

Section: Clozapine As First and Second Line Treatment For Schizophren...mentioning

confidence: 99%

Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug

Dell’Osso,

Bonelli,

Nardi

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

The current literature globally highlights the efficacy of Clozapine in several psychiatric disorders all over the world, with an FDA indication for reducing the risk of repeated suicidal behavior in patients with schizophrenia or schizoaffective disorder. A growing field of research is also stressing a possible broader beneficial effect of Clozapine in promoting neuroprotection and neurotrophism. However, this drug is linked to several life-threatening side effects, such as agranulocytosis, myocarditis and seizures, that limit its use in daily clinical practice. For this work, a search was performed on PubMed using the terms “Clozapine indications”, “Clozapine adverse effects”, “Clozapine regenerative effects”, and “Clozapine neuroplasticity” with the aim of reviewing the scientific literature on Clozapine’s treatment indications, adverse effects and potential regenerative role. The results confirmed the efficacy of clozapine in clinical practice, although limited by its adverse effects. It appears crucial to raise awareness among clinicians about the potential benefits of using Clozapine, as well educating medical personnel about its risks and the early identification of possible adverse effects and their management.

show abstract

Social withdrawal and neurocognitive correlates in schizophrenia

Donatis

Porcelli

Ronchi

et al. 2022

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Background: Social withdrawal constitutes a clinical manifestation of social dysfunction in SCZ that has a high impact on the quality of life of patients. Poor neurocognitive performance has been associated with poor functional outcome in SCZ in past studies. Nonetheless, the likely association between neurocognition and social withdrawal has never been investigated. The aim of our study was to investigate in a large and heterogeneous sample of SCZ patients cross-sectional associations between neurocognitive domains and social withdrawal.Methods: The sample included 761 SCZ patients who completed the baseline visit in the CATIE study.Neurocognition was assessed by a comprehensive battery of tests resulting in 5 domain scores and a composite score. Social withdrawal was measured by a speci c item of the Heinrichs-Carpenter Quality of Life Scale. Bivariate correlations, ANOVA and multiple regression analysis were conducted using STATISTICA software package (StatSoft, Inc. Tulsa, OK, USA). Statistical signi cance was tested at p value < 0.05.Results: Social withdrawal was associated with a lower score in the neurocognitive composite score and in "Verbal memory", "Processing speed" and "Working memory" scores. "Verbal memory" score showed the strongest association with social withdrawal. 8% of the total variance of social withdrawal was explained by these three cognitive domains and additional clinical and socio-demographic factors (education years, PANSS positive symptoms score, employment).Conclusions: Our study showed that in a large and real-world representative sample of SCZ patients, social withdrawal was associated with neurocognitive de cits involving verbal memory, processing speed and working memory domains. Our results con rmed the wide heterogeneity and speci city of the correlation between neurocognitive domains and indicators of functional outcome in SCZ, underlining the role of certain neurocognitive abilities in social withdrawal.

show abstract

Clinical and demographic factors associated with early relapse in patients with schizophrenia: a naturalistic observation study

Cited by 5 publications

References 43 publications

A Brief Psychoeducation Intervention to Prevent Rehospitalization in Severe Mental Disorder Inpatients

A Brief Psychoeducation Intervention to Prevent Rehospitalization in Severe Mental Disorder Inpatients

Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug

Social withdrawal and neurocognitive correlates in schizophrenia

Contact Info

Product

Resources

About